ABBVIE (ABBV) DIvidends Date & History

Key Takeaways

• AbbVie offers a compelling dividend yield of 3.48%, paid quarterly at $1.73 per share, annualizing to $6.92.
• The company has raised its dividend annually since its 2013 spin-off, with a recent 5.64% increase.
• Trailing payout ratio exceeds 280%, but forward estimates suggest around 43%, supported by strong free cash flow (FCF).
• FCF generation comfortably covers dividends, ensuring sustainability amid pharmaceutical sector challenges.
• Yield competitive against peers like MRK (2.4%) and AMGN (3.0%), higher than some large-cap pharma averages.
• Appeals to income-focused investors seeking reliable payouts in healthcare.

Dividend Overview

AbbVie Inc. (ABBV) maintains a shareholder-friendly dividend policy, distributing quarterly payments that provide a current yield of 3.48%. The most recent quarterly dividend stands at $1.73 per share, payable on May 15, 2026, to shareholders of record as of April 15, 2026, annualizing to $6.92. This positions AbbVie as a high-yield dividend growth stock within the pharmaceuticals sector. The company has demonstrated commitment to returning capital through consistent raises, even navigating the post-patent cliff era for its blockbuster drug Humira. Investors appreciate the blend of attractive yield and growth potential, making it a staple for income portfolios.

Dividend History and Growth

AbbVie's dividend history reflects steady escalation since its inception as a spin-off from Abbott Laboratories in 2013. Total annual payouts have climbed from $2.56 in 2013 to $6.92 in 2026, representing over 170% cumulative growth. Recent years show reliable increases: $5.92 in 2023, $6.20 in 2024, $6.56 in 2025, and $6.92 projected for 2026 following the latest hike. The company has increased its dividend every year for 12 consecutive years independently, with some analyses crediting a 54-year streak including its Abbott heritage. This track record underscores a long-term strategy prioritizing shareholder returns alongside R&D investments in immunology and oncology.

Dividend Sustainability and Payout Ratio

AbbVie's trailing twelve-month payout ratio hovers around 285%, elevated due to temporary earnings pressures from Humira's patent expiration. However, forward-looking estimates place it at 42.8-48.7%, indicating improved coverage as new drugs like Skyrizi and Rinvoq gain traction. Free cash flow (FCF), a key metric for dividend health, reached approximately $17.8-19.9 billion in recent periods, amply covering the roughly $12 billion annual dividend obligation. Moderate debt levels and robust cash generation further bolster sustainability, allowing AbbVie to maintain and grow payouts despite sector volatility.

Dividend Compared to Industry Peers

AbbVie's 3.48% yield stands competitively in the pharmaceuticals industry, surpassing the sector average of about 2.7%. Among large-cap peers, it exceeds MRK's 2.36% and AMGN's 3.04%, while trailing higher-yield names like BMY (4.3%) and PFE (over 6%). Compared to JNJ at around 3%, AbbVie's profile offers superior growth potential with a similar yield, appealing to investors balancing income and appreciation in healthcare.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It efficiently identifies dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more effectively than manual screening. Explore the AI Screener to enhance your stock selection process today.

Is This Stock Attractive for Dividend Investors?

AbbVie suits income investors prioritizing high yields with growth in the stable healthcare sector. Its 3.48% payout, backed by a history of annual increases, appeals to those building portfolios for reliable cash flow. Dividend growth enthusiasts may value the consistent raises and FCF support, positioning it well for compounding returns. Conservative investors could find comfort in AbbVie's diversified immunology and oncology pipeline, mitigating patent risks. However, the elevated trailing payout ratio warrants monitoring earnings recovery. Long-term holders seeking defensive exposure amid economic uncertainty may appreciate its profile, though sector-specific risks like drug approvals persist. Overall, it balances yield, growth, and resilience for diversified dividend strategies.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations